MiRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5576-5587

  Kasinski, Andrea L ^a   Slack, Frank J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CRE RECOMBINASE; K RAS PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA 155; MICRORNA 21; MICRORNA 34A; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCL 2 GENE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE SEVERITY; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; HETEROZYGOTE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MET GENE; MOUSE; NONHUMAN; ONCOGENE K RAS; PNEUMONIA; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICRORNAS; PROTO-ONCOGENE PROTEINS P21(RAS); REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868254278     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2001     Document Type: Article

References (42)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. U.S. Cancer Statistics Working Group. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2010 [cited 2010]. Available from: http://www.cdc.gov/uscs.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
4. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74.
5. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
6. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111\-6.
7. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005;19:643-64.
8. Tchou-Wong KM, Jiang Y, Yee H, La Rosa J, Lee TC, Pellicer A, et al. Lung-specific expression of dominant-negative mutant p53 in trans-genic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am J Respir Cell Mol Biol. 2002;27:186-93.
9. Wang Y, Zhang Z, Lubet R, You M. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene 2005;24:3042-9.
10. Wang Y, Zhang Z, Lubet RA, You M. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. Oncogene 2006;25:1277-80.
11. Du Page M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009;4:1064-72.
12. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of mi R-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26: 745-52.
13. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A micro RNA component of the p53 tumour suppressor network. Nature 2007;447: 1130-4.
14. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Mos-kovits N, et al. Transcriptional activation of mi R-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-43.
15. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of micro RNAs by p53 revealed by massively parallel sequencing: mi R-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
16. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. Micro RNA-34b and Micro RNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007;67:8433-8.
17. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced micro RNA-107 inhibits HIF-1 and tumorangiogen-esis. Proc Natl Acad Sci U S A 2010;107:6334-9.
18. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor mi R-145. Proc Natl Acad Sci U S A 2009;106:3207-12.
19. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, et al. Micro RNA-145 is regulated by DNA methylation and p53 gene muta-tion in prostate cancer. Carcinogenesis 2011;32:772-8.
20. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, et al. Coordinated regulation of cell cycle transcripts by p53-Inducible micro RNAs, mi R-192 and mi R-215. Cancer Res 2008;68:10105-12.
21. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cel cycle arrest. Cancer Res 2008;68:10094-104.
22. Esquela-Kerscher A, Slack FJ. Oncomirs-micro RNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
23. Kasinski AL, Slack FJ. Micro RNAs en route to the clinic: progress in validating and targeting micro RNAs for cancer therapy. Nat Rev Cancer 2011;11:849-64.
24. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 micro RNA family. Cell 2005;120: 635-47.
25. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of mi RNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-307.
26. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, et al. p53-independent upregulation of mi R-34a during oncogene-induced senescence represses MYC. Cell Death Differ2010;17:236-45.
27. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al.Thelet-7 micro RNAreducestumorgrowth in mouse modelsof lung cancer. Cell Cycle 2008;7:759-64.
28. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small celllung tumor development by the let-7 micro RNA family. Proc Natl Acad Sci U SA2008;105:3903-8.
29. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 micro RNA. Oncogene 2009;29:1580-7.
30. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, et al. Systemic delivery of tumor suppressor micro RNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther2011;19: 1116-22.
31. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human micro RNAgenesare frequentlylocated atfragilesitesand genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
32. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappa B signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104-7.
33. Hermeking H. The mi R-34 family in cancer and apoptosis. Cell Death Differ 2009;17:193-9.
34. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control oftrans-lation and m RNA degradation by mi RNAs and si RNAs. Genes Dev 2006;20:515-24.
35. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apo-ptosis. J Biol Chem 2008;283:6572-83.
36. Itahana K, Dimri GP, Hara E, Itahana Y, Zou Y, Desprez PY, et al.Arole forp53inmaintainingandestablishingthequiescencegrowtharrest in human cells. J Biol Chem 2002;277:18206-14.
37. Becher OJ, Holland EC Genetically engineered models have advan-tages over xenografts for preclinical studies. Cancer Res 2006;66: 3355-8, discussion 8-9.
38. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8.
39. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011;18: 1414-24.
40. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12: 89-103.
41. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
42. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFRand METreceptortyrosinekinase-alteredmicro RNAexpression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012;18:74-82.